文献速递泌尿生殖MRUS

穿刺前双参数MRI:PI-RADS第2版在不同PSA水平患者中的差异

Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
PubMed 文献 · Clin Radiol · 2018-06-09

回顾性纳入184例穿刺前接受双参数MRI并行经直肠超声引导穿刺的患者,以穿刺病理为参考标准,在PSA 10 ng/ml界值分组的两个亚组中评估PI-RADS v2诊断临床显著前列腺癌(Gleason评分≥7)的效能,并与PSA及PSA密度比较;高PSA组诊断效能好,低PSA组可能漏诊小体积临床显著前列腺癌。

要点

  • PI-RADS 4类和5类视为阳性,以穿刺病理为参考标准。
  • 高PSA组仅读者2漏诊1例临床显著前列腺癌,读者1无漏诊。
  • 低PSA组读者1和读者2分别漏诊24例中的7例和5例临床显著前列腺癌。

核心结论

  • 穿刺前双参数MRI在高PSA组检测临床显著前列腺癌效能好,但在低PSA组可能漏诊小体积临床显著前列腺癌。

研究设计与样本

  • 回顾性研究,纳入2015年6月至2017年2月间184例接受穿刺前双参数MRI后行经直肠超声引导穿刺的患者。
  • 读者1在回顾双参数MRI后行认知融合的系统穿刺联合靶向穿刺,读者2回顾性阅片双参数MRI。
  • 以穿刺病理结果为参考标准,PI-RADS 4类和5类视为阳性。
  • 按PSA 10 ng/ml界值分为低PSA组和高PSA组,比较PI-RADS与PSA及PSA密度的诊断效能(ROC曲线分析)。

诊断标准与关键数值

  • PI-RADS 4类和5类视为阳性,以穿刺病理为参考标准。
  • 低PSA组临床显著前列腺癌24/123例(19.5%),高PSA组26/61例(42.6%)。
  • 两个PSA组中,读者1或读者2的PI-RADS v2分类检测临床显著前列腺癌的效能均显著优于PSA。
  • 高PSA组读者2漏诊1例临床显著前列腺癌,读者1无漏诊;低PSA组读者1和读者2分别漏诊24例中的7例和5例。

临床应用与阅片要点

  • 在高PSA组,穿刺前双参数MRI的PI-RADS v2分类检测临床显著前列腺癌效能好。
  • 在低PSA组,穿刺前双参数MRI可能漏诊小体积临床显著前列腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To validate the diagnostic accuracy of Prostate Imaging-Reporting and Data System (PI-RADS) version 2 in detecting clinically significant prostate cancer (csPCa, Gleason score ≥7) on prebiopsy biparametric MRI (bpMRI) in patients with different prostate-specific antigen (PSA) levels.

MATERIALS AND METHODS: This retrospective study included 184 patients who underwent prebiopsy bpMRI followed by transrectal ultrasonography-guided biopsy between June 2015 and February 2017. Reader 1 performed a combination of systematic and targeted biopsy with cognitive fusion after reviewing bpMRI and reader 2 reviewed the bpMRIs retrospectively. PI-RADS categories 4 and 5 were considered positive, and the results of the biopsy were considered the reference standard. Diagnostic performance of PI-RADS of bpMRI was evaluated in two PSA groups with a PSA cut-off level of 10 ng/ml and compared to PSA and the PSA density using receiver operating characteristics (ROC) curve analysis.

RESULTS: csPCa was diagnosed in 24 of 123 patients (19.5%) and 26 of 61 patients (42.6%) in the low and high PSA groups, respectively. A PI-RADS v2 category by either readers 1 or 2 had a significantly better performance to detect csPCa than PSA in both PSA groups. In the high PSA group, only one csPCa was missed by reader 2, but none by reader 1. In the low PSA group, readers 1 and 2 were unable to detect seven and five of the 24 csPCas, respectively.

CONCLUSION: Prebiopsy bpMRI has good performance for detecting csPCa in the high PSA group but may miss small-volume csPCa in the low PSA group.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Choi MH, Lee YJ, Jung SE, et al. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels. Clin Radiol. 2018. PMID: 29895386. doi:10.1016/j.crad.2018.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。